Imagine a child fighting a relentless fever and swelling that refuses to stop. This is the reality for some kids with systemic juvenile idiopathic arthritis complicated by macrophage activation syndrome. These conditions cause the body to overreact and attack itself. Standard treatments often fail to calm this storm. What happens when those options run out? A small group of doctors looked at two specific children who received ruxolitinib, a medication that blocks inflammation pathways, alongside other therapies like steroids or plasma exchange.
Both children showed marked improvement in their systemic hyperinflammation. Their fevers resolved, and their ferritin levels, a marker of inflammation, normalized. One child stopped taking steroids within three months, while the other did so within six months. Five out of seven total cases reviewed achieved complete remission, and two achieved partial remission. No deaths were reported in this small group.
However, this story comes with important caveats. The evidence comes from just two cases at one center plus five reported elsewhere. This is a small sample size, and the design is retrospective, meaning doctors looked back at past records. One patient did develop Epstein–Barr virus–associated hemophagocytic lymphohistiocytosis and neutropenia, requiring drug discontinuation. Two patients experienced relapse during steroid tapering. Because of these limitations, we cannot say this works for everyone or that it is safe for all patients yet. It remains a potential rescue option for those with refractory disease.